Hepatitis Delta Virus and Hepatocellular Carcinoma

Area of Science:

• Hepatology
• Virology
• Oncology

Background:

• Hepatitis D virus (HDV) is a circular RNA virus requiring Hepatitis B virus (HBV) for infection and replication.
• HDV co-infection affects 12-72 million people globally, increasing risks of cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
• HDV-associated HCC presents earlier and is more aggressive than HBV-induced HCC.

Purpose of the Study:

• To comprehensively review the epidemiology, molecular biology, and immunology of HDV.
• To examine the synergistic role of HDV and HBV in liver disease progression and HCC development.
• To address the question of whether HDV is an oncogenic virus.

Main Methods:

• Literature review of existing studies on HDV and HBV.
• Analysis of epidemiological data on HDV prevalence and associated liver diseases.
• Examination of molecular and immunological mechanisms linking HDV/HBV to HCC.

Main Results:

• HDV co-infection significantly increases the risk and aggressiveness of HCC compared to HBV mono-infection.
• The molecular profile of HDV-associated HCC is distinct from HBV-induced HCC.
• Mechanisms of synergistic carcinogenicity involve chronic inflammation, immune dysregulation, and potential direct oncogenic effects of HDV.

Conclusions:

• HDV plays a critical role in the pathogenesis of severe liver disease and aggressive HCC.
• Further research is needed to fully elucidate the oncogenic potential of HDV.
• Understanding HDV's unique contribution is crucial for developing targeted therapies and prevention strategies.